GlassScriptPhysician profile
Carlye N Ward
NPI 1760969174
$4,112.00
in general payments reported to CMS, 2019-2025
31 companies · $921 in 2025
The $921 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $769 · 2023: $929 · 2024: $769 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.70 |
| Education | $221.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.19 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $431.18 | 2022-2025 | |
| Astellas Pharma US INC | $362.62 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $345.50 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $323.04 | 2021-2024 | Injectafer |
| Therapeuticsmd, INC. | $312.14 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $250.20 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $220.12 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Agile Therapeutics, INC. | $160.19 | 2021-2024 | Twirla |
| Pfizer INC. | $139.63 | 2021-2024 | |
| Organon LLC | $131.32 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $130.15 | 2021-2022 | |
| Evofem Biosciences, INC. | $126.60 | 2021-2025 | Phexxi, Solosec, Phexx |
| Medical Device Business Services, INC. | $122.62 | 2024 | |
| Sage Therapeutics, LLC | $88.12 | 2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $80.22 | 2021-2024 | |
| Smith+Nephew, INC. | $77.46 | 2025 | Pico 14 |
| Exeltis, USA INC. | $66.79 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $57.44 | 2021-2025 | Thinprep 2000 Processor |
| Scynexis, INC. | $45.04 | 2022 | |
| Integra Lifesciences Corporation | $35.71 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Exact Sciences Corporation | $19.88 | 2025 | The Cologuard Plus Collection Kit |
| Davol INC. | $18.16 | 2024 | Arista Ah Flexitip |
| Qiagen, LLC | $17.35 | 2022 | |
| Becton, Dickinson and Company | $16.79 | 2023 | Bd Onclarity |
| Medicem INC. | $15.73 | 2021 | |
| Ascend Therapeutics US, LLC | $15.56 | 2021 | |
| Avion Pharmaceuticals | $15.03 | 2021 | |
| Millicent US INC | $15.01 | 2024 | Intrarosa, Femring |
| Lupin INC. | $14.45 | 2021 | |
| Merck Sharp & Dohme LLC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlye Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.